{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:12:22Z","timestamp":1790140342530,"version":"4.0.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Prospective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2<\/jats:italic>)\u2013positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.<\/jats:p><\/jats:sec>Interventions<\/jats:title>PRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy\u2014Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Changes in PRO measure scores and subscores over time.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2<\/jats:italic>-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P<\/jats:italic>\u2009=\u2009.04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P<\/jats:italic>\u2009=\u2009.001), whereas function, pain, and edema subscores were not significantly different than baseline.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02945579<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.33933","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:34:11Z","timestamp":1694705651000},"page":"e2333933","source":"Crossref","is-referenced-by-count":14,"title":["Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Helen M.","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia J.","family":"Diego","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei T.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie X.","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona F.","family":"Shaitelman","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[{"name":"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"White","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Exceptional Responders Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya W","family":"Moseley","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica WT","family":"Leung","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Huang","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind P","family":"Candelaria","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E","family":"Adrada","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Arribas","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel FD","family":"van la Parra","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K","family":"Hunt","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bedrosian","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mediget","family":"Teshome","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa F","family":"Hwang","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makesha V","family":"Miggins","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P","family":"Refinetti","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Ehlers","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Suarez Colen","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E","family":"Loveland-Jones","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Lesnikowski","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Samiian","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton D","family":"Chong","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"5","key":"zoi230979r1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.11238","article-title":"Patient-reported outcome measures in clinical research.","volume":"328","author":"Weinfurt","year":"2022","journal-title":"JAMA"},{"key":"zoi230979r2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization.","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"5","key":"zoi230979r3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/jnci\/djy181","article-title":"Blinding and patient-reported outcome completion rates in US Food and Drug Administration cancer trial submissions, 2007-2017.","volume":"111","author":"Roydhouse","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi230979r4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jbmt.2019.02.009","article-title":"Commentary: Statistical significance and clinical significance\u2014a call to consider patient reported outcome measures, effect size, confidence interval and minimal clinically important difference (MCID).","volume":"23","author":"Fleischmann","year":"2019","journal-title":"J Bodyw Mov Ther"},{"issue":"5","key":"zoi230979r5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension.","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi230979r6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"19","key":"zoi230979r7","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1001\/jama.2022.6421","article-title":"Ethical considerations for the inclusion of patient-reported outcomes in clinical research: the PRO ethics guidelines.","volume":"327","author":"Cruz Rivera","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"zoi230979r8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cncr.v126.5","article-title":"Patient-reported outcomes in the Translational Breast Cancer Research Consortium.","volume":"126","author":"Bowen","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"zoi230979r9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/XCS.0000000000000670","article-title":"Eliminating breast surgery for invasive cancer with exceptional response to neoadjuvant systemic therapy: prospective multicenter clinical trial planned initial feasibility endpoint.","volume":"237","author":"Johnson","year":"2023","journal-title":"J Am Coll Surg"},{"issue":"12","key":"zoi230979r10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi230979r11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X03256005","article-title":"Validation of a decision regret scale.","volume":"23","author":"Brehaut","year":"2003","journal-title":"Med Decis Making"},{"issue":"12","key":"zoi230979r12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/1097-0142(20010615)91:12<2273::AID-CNCR1258>3.0.CO;2-1","article-title":"Form or function? Part 1. Subjective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy.","volume":"91","author":"Stanton","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"zoi230979r13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1012278023233","article-title":"The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively.","volume":"68","author":"Coster","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"zoi230979r15","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1002\/cam4.1881","article-title":"Improved long-term patient-reported health and well-being outcomes of early-stage breast cancer treated with partial breast proton therapy.","volume":"7","author":"Teichman","year":"2018","journal-title":"Cancer Med"},{"issue":"6","key":"zoi230979r17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0272989X16636113","article-title":"Extent and predictors of decision regret about health care decisions: a systematic review.","volume":"36","author":"Becerra P\u00e9rez","year":"2016","journal-title":"Med Decis Making"},{"issue":"4","key":"zoi230979r18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0272989X14564432","article-title":"Decision regret following treatment for localized breast cancer: is regret stable over time?","volume":"35","author":"Martinez","year":"2015","journal-title":"Med Decis Making"},{"issue":"2","key":"zoi230979r19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2019.01.089","article-title":"Local therapy decisional regret in older women with breast cancer: a population-based study.","volume":"104","author":"Advani","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"zoi230979r20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ijrobp.2020.04.041","article-title":"Patient-reported outcomes and cosmesis after once-weekly hypofractionated breast irradiation in medically underserved patients.","volume":"107","author":"Eldredge-Hindy","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi230979r21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijrobp.2021.05.004","article-title":"Five-year longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation.","volume":"111","author":"Weng","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"zoi230979r22","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00520-017-3824-3","article-title":"Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis.","volume":"25","author":"Leysen","year":"2017","journal-title":"Support Care Cancer"},{"issue":"5","key":"zoi230979r23","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.3390\/curroncol29050251","article-title":"Patient-reported outcomes measurement in radiation oncology: interpretation of individual scores and change over time in clinical practice.","volume":"29","author":"Kwon","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"zoi230979r24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11136-020-02652-w","article-title":"Patient-reported outcomes in survivors of breast cancer one, three, and five years post-diagnosis: a cancer registry-based feasibility study.","volume":"30","author":"Skandarajah","year":"2021","journal-title":"Qual Life Res"},{"issue":"7","key":"zoi230979r25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery.","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"issue":"4","key":"zoi230979r26","article-title":"Targeted axillary dissection in node-positive breast cancer: a retrospective study and cost analysis.","volume":"13","author":"Beniey","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"zoi230979r27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.33184","article-title":"Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): a lymphedema prevention intervention trial for newly diagnosed breast cancer patients.","volume":"127","author":"Naughton","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"zoi230979r28","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1002\/cncr.23891","article-title":"Breast cancer survivors\u2019 health-related quality of life: racial differences and comparisons with noncancer controls.","volume":"113","author":"Paskett","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"zoi230979r29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-016-3965-y","article-title":"Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors.","volume":"159","author":"Pinheiro","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"zoi230979r30","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an american society of clinical oncology and association of community cancer centers joint research statement.","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230979r31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1245\/s10434-022-12570-5","article-title":"The role of cryoablation in breast cancer beyond the oncologic control: COST and Breast-Q patient-reported outcomes.","volume":"30","author":"Khan","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"zoi230979r32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11864-020-00782-4","article-title":"Health-related quality of life and patient-reported outcomes in radiation oncology clinical trials.","volume":"21","author":"Remick","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"zoi230979r33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015276414526","article-title":"Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening.","volume":"11","author":"Cella","year":"2002","journal-title":"Qual Life Res"},{"key":"zoi230979r14","unstructured":"Ottawa Hospital Research Institute. User manual\u2014decision regret scale. Accessed September 19, 2022. https:\/\/decisionaid.ohri.ca\/docs\/develop\/User_manuals\/UM_Regret_Scale.pdf"},{"key":"zoi230979r16","unstructured":"FACIT. FACT-B+4 scoring guidelines (version 4). Accessed September 19, 2022. https:\/\/www.facit.org\/measures-scoring-downloads\/fact-b%2B4-scoring-downloads"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809386\/johnson_2023_oi_230979_1693946367.77717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:34:24Z","timestamp":1694705664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809386"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.33933","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}